Table 4 The various drug price calculation methods applied
Drug price calculation method | Ultra-orphan drugs | Orphan drugs | Non-orphan drugs | |||
|---|---|---|---|---|---|---|
All | 35 | (100%) | 81 | (100%) | 277 | (100%) |
Similar efficacy comparison method (I) | 11 | (31.4%) | 51 | (63.0%) | 176 | (63.5%) |
Similar efficacy comparison method (II) | 0 | (0%) | 3 | (3.7%) | 34 | (12.3%) |
Cost accounting method | 24 | (68.6%) | 27 | (33.3%) | 63 | (22.7%) |
Special provisions for new medical combination drugs | 0 | (0%) | 0 | (0%) | 2 | (0.7%) |
Special provisions for new drugs for which racemic or prior products exist | 0 | (0%) | 0 | (0%) | 1 | (0.4%) |
Special provisions for new drugs that are optically split from a previously-listed drug (racemic) | 0 | (0%) | 0 | (0%) | 1 | (0.4%) |